Investors bought shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading hours on Friday. $78.25 million flowed into the stock on the tick-up and $50.87 million flowed out of the stock on the tick-down, for a money net flow of $27.38 million into the stock. Of all companies tracked, Eli Lilly and had the 18th highest net in-flow for the day. Eli Lilly and traded down ($0.72) for the day and closed at $79.06

A number of research analysts recently issued reports on LLY shares. TheStreet raised shares of Eli Lilly and from a “hold” rating to a “buy” rating in a research report on Friday, May 27th. Credit Suisse Group AG reissued a “buy” rating on shares of Eli Lilly and in a research report on Thursday, May 26th. Jefferies Group reissued a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research report on Friday, May 13th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price target for the company in a research report on Friday, July 29th. Finally, BMO Capital Markets reissued a “buy” rating and set a $94.00 price target on shares of Eli Lilly and in a research report on Wednesday, July 27th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $96.35.

The firm’s 50-day moving average is $80.82 and its 200 day moving average is $75.97. The stock has a market cap of $83.62 billion and a price-to-earnings ratio of 34.08.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. During the same period in the previous year, the company posted $0.90 earnings per share. The firm had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Co. will post $3.59 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be given a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 2.58%. The ex-dividend date is Thursday, August 11th.

In related news, Director Jackson P. Tai acquired 2,560 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The stock was purchased at an average cost of $80.42 per share, with a total value of $205,875.20. Following the transaction, the director now directly owns 42,110 shares of the company’s stock, valued at approximately $3,386,486.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $75.12, for a total transaction of $15,024,000.00. Following the completion of the transaction, the insider now directly owns 127,090,804 shares of the company’s stock, valued at $9,547,061,196.48. The disclosure for this sale can be found here.

Other institutional investors recently made changes to their positions in the company. BlackRock Advisors LLC raised its position in shares of Eli Lilly and by 13.9% in the fourth quarter. BlackRock Advisors LLC now owns 5,480,332 shares of the company’s stock valued at $461,773,000 after buying an additional 667,576 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Eli Lilly and by 3.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 3,586,902 shares of the company’s stock valued at $302,233,000 after buying an additional 129,362 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Eli Lilly and by 81.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 272,917 shares of the company’s stock valued at $22,996,000 after buying an additional 122,779 shares during the last quarter. Eaton Vance Management raised its position in shares of Eli Lilly and by 3.6% in the fourth quarter. Eaton Vance Management now owns 2,889,176 shares of the company’s stock valued at $243,442,000 after buying an additional 99,792 shares during the last quarter. Finally, Ashburton Jersey Ltd bought a new position in shares of Eli Lilly and during the fourth quarter valued at approximately $7,411,000.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.